Progress in targeting therapy for hepatic cancer
Uchino, J.; Une, Y.; Kamiya, T.; Kawata, A.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 21(6): 765-771
1994
ISSN/ISBN: 0385-0684 PMID: 8185333 Document Number: 429966
Targeting therapy for hepatic cancer is divided into a method using Lipiodol as drug carrier and a method employing immunological responses of monoclonal antibodies to the tumor antigens. For the latter method, immuno-conjugates of antibodies and cytotoxic agents have been studied. Because of the lower response rates of conventional chemotherapy. Lipiodol as drug carrier provides the most effective targeting therapy on hepatic cancer at the present time. Immunotherapy using cytotoxic cells, however, did not result in sufficient clinical efficacy on the liver cancer. The system for accumulation of the effective and sufficient number of cytotoxic cells or immunoconjugates in the targeting tumor tissues are expected to be investigated.